Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

28.57
-5.0100-14.92%
Post-market: 28.570.00000.00%16:38 EDT
Volume:1.35M
Turnover:40.95M
Market Cap:1.86B
PE:-9.58
High:33.52
Open:33.14
Low:28.34
Close:33.58
Loading ...

BMO Capital Initiates Kymera Therapeutics at Market Perform With $55 Price Target

MT Newswires Live
·
06 Dec 2024

Kymera Therapeutics Initiated at Market Perform by BMO Capital

Dow Jones
·
06 Dec 2024

Kymera Therapeutics Shares Rise After Upgrade From Wells Fargo

MT Newswires Live
·
03 Dec 2024

Wells Fargo Upgrades Kymera Therapeutics to Overweight, Price Target is $57

MT Newswires Live
·
02 Dec 2024

Kymera Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
02 Dec 2024

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

GlobeNewswire
·
26 Nov 2024

Kymera Therapeutics (KYMR) Gets a Hold from Wells Fargo

TIPRANKS
·
25 Nov 2024

U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix

Reuters
·
19 Nov 2024

Kymera Therapeutics Initiated at Overweight by Stephens & Co.

Dow Jones
·
18 Nov 2024

Kymera Therapeutics initiated with an Overweight at Stephens

TIPRANKS
·
18 Nov 2024

Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)

TIPRANKS
·
05 Nov 2024

Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)

TIPRANKS
·
05 Nov 2024

Kymera Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
05 Nov 2024

UBS Adjusts Price Target on Kymera Therapeutics to $74 From $80, Maintains Buy Rating

MT Newswires Live
·
04 Nov 2024

Kymera Therapeutics Price Target Cut to $53.00/Share From $54.00 by Truist Securities

Dow Jones
·
01 Nov 2024

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

Zacks
·
01 Nov 2024

Kymera Therapeutics price target raised to $52 from $45 at Guggenheim

TIPRANKS
·
01 Nov 2024

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber

Reuters
·
01 Nov 2024

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com
·
01 Nov 2024

Kymera Therapeutics Inc : Truist Securities Cuts Target Price to $53 From $54

THOMSON REUTERS
·
01 Nov 2024